Investigating ERO1α, IDO1 and MHC Class I : potential proteins that can be manipulated to change the tumour microenvironment from ‘cold’ to ‘hot’

ERO1α, a cancer-associated protein, and IDO1, an immunomodulatory enzyme, have been shown to be associated with the expression of MHC Class I proteins. Previous study done by our lab that showed ERO1α association with hypoxic tumour progression, also had preliminary data indicating that under hypoxi...

Full description

Saved in:
Bibliographic Details
Main Author: Peck, Jia Yi
Other Authors: Sze Siu Kwan
Format: Final Year Project
Language:English
Published: Nanyang Technological University 2020
Subjects:
Online Access:https://hdl.handle.net/10356/143295
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:ERO1α, a cancer-associated protein, and IDO1, an immunomodulatory enzyme, have been shown to be associated with the expression of MHC Class I proteins. Previous study done by our lab that showed ERO1α association with hypoxic tumour progression, also had preliminary data indicating that under hypoxia, there is an increase in amino acid tryptophan catabolism by IDO1. However, there is still no direct linkage found between these 3 proteins, which could be potentially manipulated to turn the tumour microenvironment (TME) from ‘cold’ to ‘hot’. In this study, we investigated the effects of inhibiting ERO1α and IDO1 on MHC Class I and ERO1α expression. We discovered that MHC Class I expression increased while ERO1α expression decreased upon ERO1α inhibition and IDO1 inhibition. IDO1 expression also increased under hypoxia. SILAC proteomics method was used to gain insight on proteins upregulated and downregulated after IDO1 inhibition. Results showed that proteins involved in immune activation were upregulated, particularly immunoglobulins. These results provide insights on potential interactions between ERO1α, IDO1, and MHC Class I in the TME which could be potential immunotherapy targets in the future.